Skip to content
Sign in
Health · North America

FDA approves phentolamine eye drops for adults with presbyopia

The FDA expanded Viatris’ 0.75% Ryzumvi’s use to adults with presbyopia, adding a new option for age-related near-vision difficulty. Once-nightly dosing met the primary endpoint in two phase 3 trials; conjunctival hyperemia was the most common reported adverse event.

AI-assisted synthesis · Based on 5 outlets' reporting · Article text read from 2 of 5 outlets · 1 article captured only in partHow it's made

View timeline · 6 entries
5 outletsLatest reporting 2 min read
Coverage: Too few ratedL 0 · C 1 · R 0 · 4 unrated
File photo
Photo: The U.S. Food and Drug Administration / Wikimedia Commons (Public domain)

What happened

Key facts

  • The FDA approved phentolamine ophthalmic drops.
  • The approved treatment is for adults with presbyopia.

The brief

The FDA has approved Viatris’s Ryzumvi eye drops for treating presbyopia in adults, adding a new use for a prescription solution containing 0.75% phentolamine. The approval makes the product available for the age-related vision condition; the sources do not state when the decision took effect.

Pharmacy Times describes Ryzumvi as a once-nightly treatment and reports that it met the primary endpoint in two phase 3 studies, MIRA-2 and MIRA-3. The combined trials randomly assigned 902 adults aged 40 to 64. Pharmacy Times also says the solution achieved key secondary goals, but the report does not provide results for those goals in detail.

The most common reported adverse event was conjunctival hyperemia, according to Pharmacy Times. That report does not give a frequency for the event. Medscape’s account, based on a Viatris press release, focuses on directions for use rather than trial outcomes or adverse events.

The product already had a separate FDA-approved use: Medscape reports that the agency authorized Ryzumvi in 2023 to reverse pharmacologically induced pupil dilation in adults and children aged 3 or older. The new approval covers presbyopia in adults, while the earlier use covered pupil dilation in a wider age range.

Medscape says patients should avoid letting the vial tip touch the eye or another surface, a precaution intended to reduce the risk of eye injury or contamination. Contact lens wearers should remove their lenses before dosing and wait at least 10 minutes before putting them back in, according to the same account.

Viatris markets Ryzumvi, and its press release is the basis Medscape cites for the approval and use instructions. Pharmacy Times provides the clinical-trial details and adverse-event account.

Together, the reports describe the regulatory decision, the evidence cited for the new indication, and practical precautions for patients, but do not give a presbyopia-specific dosing schedule beyond Pharmacy Times’s description of once-nightly use.

Why it matters

  • The approval gives adults with presbyopia another prescription eye-drop option, expanding a market that already includes pilocarpine drops such as Vuity. For patients seeking to reduce reliance on reading glasses for close-up tasks, the treatment may offer an alternative, while its use will depend on individual suitability and tolerance of side effects such as eye redness.

What to watch next

  • Whether Viatris provides further prescribing details for Ryzumvi’s adult presbyopia use, including the dosing schedule.
  • How the trial findings from MIRA-2 and MIRA-3 are presented in prescribing information for the newly approved use.
  • Whether additional reporting specifies the frequency of conjunctival hyperemia associated with the treatment.

How it's being covered

Coverage analysisShow details
5 source articles · 5 unique outlets
Outlet political mix: Too few rated· 1 Center · 4 unrated
Where the outlets are based: Unknown 100%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
1 outlet
0 outlets
The marker shows coverage balance: each unique outlet counts once. 4 unrated outlets are not included.
Geography
Where the outlets covering this story are based.
5 unique outlets
Coverage imbalance
  • Coverage is currently concentrated among outlets based in Unknown (5 of 5 geographically-identified sources).
How we measure coverage

One source is from a wire service (AP, Reuters, AFP or Bloomberg), whose reporting other outlets often republish.

How outlets' accounts compare

1 framing difference · 1 uncorroborated claim
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read; 3 other outlets were checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • Pharmacy Times emphasizes the two phase 3 trials, their 902 participants, and conjunctival hyperemia; Medscape emphasizes Ryzumvi’s earlier pupil-dilation approval and patient-use precautions.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • Pharmacy Times reports that conjunctival hyperemia was the most common adverse event, without giving its frequency.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. Congress adopted the name “Food and Drug Administration” for the agency.
    Background · compiled and fact-checked by Updat3
  2. Congress passed the Federal Food, Drug, and Cosmetic Act, establishing the FDA’s authority to review drugs before marketing and oversee their safety.
    Background · compiled and fact-checked by Updat3
  3. President John F. Kennedy signed the Kefauver-Harris Amendments, requiring evidence of drug effectiveness as well as safety.
    Background · compiled and fact-checked by Updat3
  4. In October 2021, the FDA had approved Vuity, a pilocarpine eye drop, as the first prescription eye-drop treatment for adults with presbyopia.
    Background · from our historical context
  5. The FDA approved Ryzumvi in 2023 to treat pharmacologically induced pupil dilation in adults and children aged 3 years or older.
    Reported in this story's sourcesSource:medscape.com
  6. The FDA approved Qlosi, a pilocarpine eye drop, for adults with presbyopia.
    Background · compiled and fact-checked by Updat3

How we got here

On September 22, 2023, the U.S. Food and Drug Administration approved Ryzumvi, a 0.75% phentolamine ophthalmic solution, to reverse pharmacologically induced pupil dilation in adults and children aged 3 and older. That earlier approval established Ryzumvi’s first U.S. indication before its later use was considered for presbyopia.

In October 2021, the FDA had approved Vuity, a pilocarpine eye drop, as the first prescription eye-drop treatment for adults with presbyopia. The FDA’s 2021 Vuity approval marked a regulatory milestone for that approach, and the agency approved another pilocarpine product, Qlosi, in October 2023.

Original sources

5 articles from 5 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.